• Shares of DuPont Fabros Technology advanced 9.8% following news that Digital Realty Trust Inc (DLR - Free Report) agreed to acquire DuPont Fabros for about $7.6 billion
• Endo International plc’s shares tanked 16.6% after U.S. Food and Drug Administration requested Endo to remove its opioid pain medication from the market
• Shares of Pandora Media, Inc. gained 1.2% after Sirius XM Holdings (SIRI - Free Report) declared that it would make $480 million strategic cash investment in Pandora Media
• Lexicon Pharmaceuticals, Inc.’s (LXRX - Free Report) shares increased 6.8% after the company reported positive top-line results from its Phase 3 inTandem3 study of sotagliflozin for treatment of patients with type 1 diabetes
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
• Shares of DuPont Fabros Technology advanced 9.8% following news that Digital Realty Trust Inc (DLR - Free Report) agreed to acquire DuPont Fabros for about $7.6 billion
• Endo International plc’s shares tanked 16.6% after U.S. Food and Drug Administration requested Endo to remove its opioid pain medication from the market
• Shares of Pandora Media, Inc. gained 1.2% after Sirius XM Holdings (SIRI - Free Report) declared that it would make $480 million strategic cash investment in Pandora Media
• Lexicon Pharmaceuticals, Inc.’s (LXRX - Free Report) shares increased 6.8% after the company reported positive top-line results from its Phase 3 inTandem3 study of sotagliflozin for treatment of patients with type 1 diabetes
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SIRI - FREE
Get the latest research report on DLR - FREE
Get the latest research report on LXRX - FREE